Johnson & Johnson tops Street 2Q forecasts

Cmg Food

Johnson & Johnson posted second-quarter profit earnings that beat analysts' estimates, aided by the growing pharmaceutical division that is home to blockbuster products such as arthritis treatment Remicade. The company added about 10.9 percent in value since last earnings when it was at $110.93. The stock's price to price to book (P/B) ratio for most recent quarter was disclosed as 0.97.

Overall, the average earnings surprise was 2.1 percent over the past four quarters. The dividend provided 2.6 percent yield, which was slightly lower than the five-year average yield of 2.8 percent.

The company increased its sales guidance for the full year to between $71.5 billion and $72.2 billion, and its adjusted full-year earnings per share guidance to between $6.63 and $6.73. The stock gained 4.96% the day following the earnings was released, and on 7th day price change was 8.26%.

A number of research analysts have recently commented on JNJ shares. The stock traded down to $122.71 during the day, due to lack of any buying support eventually closed down at $123.00 with a loss of -0.15% for the day.

That amounts to a 11.5% bottom-line slide as sales grew approximately 3.9% compared with the same period in 2015. The company's revenue was up.6% compared to the same quarter a year ago. The remarkable sales forecast has been decided at $76.15B while reduced sales figure was expected at $74.05B. Analysts' average estimate stands at $6.61, so we can expect that to come up. Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to "Sell", Price Target of the shares are set at $94.Company shares were Reiterated by RBC Capital Mkts on April 20, 2016 to "Outperform", Firm has raised the Price Target to $ 125 from a previous price target of $122.Company shares were Reiterated by Piper Jaffray on April 20, 2016 to "Neutral", Firm has raised the Price Target to $ 106 from a previous price target of $105.

On 7/15/2016, Johnson & Johnson (NYSE:JNJ) finished the previous buying and selling session with the price of $123.00.

Johnson & Johnson's stock has returned almost 27% over the last 12 months, while that of its competitor Pfizer (PFE) has risen by 7.4%. The share price has declined -0.6% from its best level in 52 weeks and dropped 21.47% this year. The total traded volume was 7,192,765 shares. The stock has broken out of a narrow, 2-week trading range and has set a new high for the year.

Related news: